115 lines
77 KiB
Text
115 lines
77 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK148852">
|
|
<meta name="ncbi_domain" content="mlprobe">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK148852/?report=reader">
|
|
<meta name="ncbi_pagename" content="Development of a Second Generation mGlu3 NAM Probe - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Development of a Second Generation mGlu3 NAM Probe - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/mlprobe/ml338/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/mlprobe/ml336/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/mlprobe/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Probe Reports from the NIH Molecular Libraries Program [Internet]">
|
|
<meta name="citation_title" content="Development of a Second Generation mGlu3 NAM Probe">
|
|
<meta name="citation_publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="citation_date" content="2013/03/22">
|
|
<meta name="citation_author" content="Cody Wenthur">
|
|
<meta name="citation_author" content="J. Scott Daniels">
|
|
<meta name="citation_author" content="Ryan Morrison">
|
|
<meta name="citation_author" content="Julie L. Engers">
|
|
<meta name="citation_author" content="Colleen M. Niswender">
|
|
<meta name="citation_author" content="P. Jeffrey Conn">
|
|
<meta name="citation_author" content="Craig W. Lindsley">
|
|
<meta name="citation_pmid" content="23885366">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK148852/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Development of a Second Generation mGlu3 NAM Probe">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="DC.Contributor" content="Cody Wenthur">
|
|
<meta name="DC.Contributor" content="J. Scott Daniels">
|
|
<meta name="DC.Contributor" content="Ryan Morrison">
|
|
<meta name="DC.Contributor" content="Julie L. Engers">
|
|
<meta name="DC.Contributor" content="Colleen M. Niswender">
|
|
<meta name="DC.Contributor" content="P. Jeffrey Conn">
|
|
<meta name="DC.Contributor" content="Craig W. Lindsley">
|
|
<meta name="DC.Date" content="2013/03/22">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK148852/">
|
|
<meta name="description" content="Herein we report the discovery and structure activity relationship (SAR) of a novel, second generation metabotropic glutamate receptor 3 (mGlu3) negative allosteric modulator (NAM) probe (ML337) with >50-fold selectivity versus mGlu2 (IC50 >30 μM). The mGlu3 NAM was discovered via an iterative parallel synthesis optimization of the first generation mGlu3 NAM ML289, that was only ~15-fold selective. This mGlu3 NAM (60204017, ML337) displays an IC50 value of 592 nM and is inactive (>30 μM) on mGlu2 (as well as mGlu1,4,5,6,7,8) and clean in a Ricerca ancillary pharmacology panel. ML337 possesses favorable physiochemical properties, a good dystrophia myotonica protein kinase (DMPK) profile and is centrally penetrant. Thus, ML337 is a best-in-class in vitro and in vivo probe for studying non-competitive antagonism of mGlu3.">
|
|
<meta name="og:title" content="Development of a Second Generation mGlu3 NAM Probe">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Herein we report the discovery and structure activity relationship (SAR) of a novel, second generation metabotropic glutamate receptor 3 (mGlu3) negative allosteric modulator (NAM) probe (ML337) with >50-fold selectivity versus mGlu2 (IC50 >30 μM). The mGlu3 NAM was discovered via an iterative parallel synthesis optimization of the first generation mGlu3 NAM ML289, that was only ~15-fold selective. This mGlu3 NAM (60204017, ML337) displays an IC50 value of 592 nM and is inactive (>30 μM) on mGlu2 (as well as mGlu1,4,5,6,7,8) and clean in a Ricerca ancillary pharmacology panel. ML337 possesses favorable physiochemical properties, a good dystrophia myotonica protein kinase (DMPK) profile and is centrally penetrant. Thus, ML337 is a best-in-class in vitro and in vivo probe for studying non-competitive antagonism of mGlu3.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK148852/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-mlprobe-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/mlprobe/ml337/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK148852/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8CD21C7D66B67100000000000F000D.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK148852/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/mlprobe/ml338/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Development of a Second Generation mGlu3 NAM Probe</div><div class="j">Probe Reports from the NIH Molecular Libraries Program [Internet]</div></div><div class="tail"><a href="/books/n/mlprobe/ml336/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK148852/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK148852/&text=Development%20of%20a%20Second%20Generation%20mGlu3%20NAM%20Probe"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/mlprobe/?report=reader">Title Information</a><a href="/books/n/mlprobe/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK148852/?report=classic">Switch to classic view</a><a href="/books/NBK148852/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK148852%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8CD21C7D66B67100000000000F000D.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK148852_"><span class="title" itemprop="name">Development of a Second Generation mGlu<sub>3</sub> NAM Probe</span></h1><p class="contribs">Wenthur C, Daniels JS, Morrison R, et al.</p><p class="fm-aai"><a href="#_NBK148852_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="_abs_rndgid_" itemprop="description"><p>Herein we report the discovery and structure activity relationship (SAR) of a novel, second generation metabotropic glutamate receptor 3 (mGlu<sub>3</sub>) negative allosteric modulator (NAM) probe (<a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=abstract&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a>) with >50-fold selectivity versus mGlu<sub>2</sub> (IC<sub>50</sub> >30 μM). The mGlu<sub>3</sub> NAM was discovered via an iterative parallel synthesis optimization of the first generation mGlu<sub>3</sub> NAM <a href="/pcsubstance/?term=ML289[synonym]" ref="pagearea=abstract&targetsite=entrez&targetcat=term&targettype=pubchem">ML289</a>, that was only ~15-fold selective. This mGlu<sub>3</sub> NAM (60204017, <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=abstract&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a>) displays an IC<sub>50</sub> value of 592 nM and is inactive (>30 μM) on mGlu<sub>2</sub> (as well as mGlu<sub>1,4,5,6,7,8</sub>) and clean in a Ricerca ancillary pharmacology panel. <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=abstract&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> possesses favorable physiochemical properties, a good dystrophia myotonica protein kinase (DMPK) profile and is centrally penetrant. Thus, <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=abstract&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> is a best-in-class <i>in vitro</i> and <i>in vivo</i> probe for studying non-competitive antagonism of mGlu<sub>3</sub>.</p></div><div class="h2"></div><p><b>Assigned Assay Grant #:</b> R01 NS031373</p><p><b>Screening Center Name & PI:</b> A Medicinal Chemistry FastTrack</p><p><b>Chemistry Center Name & PI:</b> Vanderbilt Specialized Chemistry Center for Accelerated Probe Development, Craig W. Lindsley</p><p><b>Assay Submitter & Institution:</b> P. Jeffrey Conn, Vanderbilt University</p><p><b>PubChem Summary Bioassay Identifier (AID):</b>
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/612451" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">612451</a></p><div id="ml337.s1"><h2 id="_ml337_s1_">Probe Structure & Characteristics</h2><div id="ml337.fu1" class="figure bk_fig"><div class="graphic"><img src="/books/NBK148852/bin/ml337fu1.jpg" alt="ML337." /></div><h3><span class="title">ML337</span></h3></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml337tu1"><a href="/books/NBK148852/table/ml337.tu1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figml337tu1" rid-ob="figobml337tu1"><img class="small-thumb" src="/books/NBK148852/table/ml337.tu1/?report=thumb" src-large="/books/NBK148852/table/ml337.tu1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="ml337.tu1"><a href="/books/NBK148852/table/ml337.tu1/?report=objectonly" target="object" rid-ob="figobml337tu1">Table</a></h4></div></div></div><div id="ml337.s2"><h2 id="_ml337_s2_">1. Recommendations for Scientific Use of the Probe</h2><p><a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> (CID 60204017) is the most potent (IC<sub>50</sub> = 592 nM, 0.3%) and selective mGlu<sub>3</sub> NAM reported to date with >60-fold selectivity vs. mGlu<sub>2</sub> as well as mGlu<sub>1,4,5,6,7,8</sub> (> 30 μM). <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> can be used both <i>in vitro</i> and <i>in vivo</i> to study the role of selective inhibition of mGlu<sub>3</sub> in the CNS in a manner previously unavailable with the prior art compounds. Moreover, <a href="/pcsubstance/?term=ML289[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML289</a> possess an attractive <i>in vitro</i> and <i>in vivo</i> DMPK profile, ancillary pharmacology (only two activities at 70% inhibition @10 μM in the Ricerca Panel) and affords excellent CNS exposure in both mouse (brain:plasma ratio of 0.92) and rat (brain:plasma ratio of 0.3). <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> can be used for basic biochemical and electrophysiological experiments as well as to help establish potential utility for mGlu<sub>3</sub> inhibition as a target for a wide variety of important CNS therapeutic indications.</p></div><div id="ml337.s3"><h2 id="_ml337_s3_">2. Materials and Methods</h2><p><b>Cell culture.</b> Human Embryonic Kidney (HEK-293) cell lines co-expressing mGlu 2, 3, 4, 6, 7 or 8 and GIRK potassium channels were grown in growth medium containing 45% DMEM, 45% F-12, 10% FBS, 20 mM HEPES, 2 mM L-glutamine, antibiotic/antimycotic non-essential amino acids, 700 μg/ml G418, and 0.6 μg/ml puromycin. Rat mGlu<sub>1</sub> and mGlu<sub>5</sub> cells were cultured as described in Hempstapat et al., 2007. TREx293 cells stably expressing mGlu<sub>3</sub> and the promiscuous G protein Galpha15 were grown in Dulbecco’s Modified Eagle Media (DMEM), 10% Tet-tested fetal bovine serum (Atlanta Biologicals), 100 units/ml penicillin/streptomycin, 20 mM HEPES (pH 7.3), 1 mM sodium pyruvate, 2 mM glutamine, 1× MEM Non-Essential Amino Acids Solution, 500 ug/ml G418 (Mediatech, Inc., Herndon, VA), 100 μg/mL hygromycin, and 5 μg/mL blasticidin S (Growth Media). Cells for experiments were generally maintained for approximately 15–20 passages. All cell culture reagents were purchased from Invitrogen Corp. (Carlsbad, CA) unless otherwise noted. All cells were maintained at 37 °C in the presence of 5% CO<sub>2</sub>. All cell culture reagents were purchased from Invitrogen Corp. (Carlsbad, CA) unless otherwise noted.</p><p><b>Calcium mobilization assays.</b> Calcium assays were used to assess activity of compounds at mGlus 1, 3, and 5. Briefly, mGlu<sub>3</sub> TREx293, mGlu<sub>1</sub>, and mGlu<sub>5</sub> cells were plated into 384 well, black-walled, clear-bottom poly-D-lysine coated plates (Greiner) at a density of 15,000 cells/20 μL/well in DMEM containing 10% dialyzed FBS, 20 mM HEPES, and 100 units/ml penicillin/streptomycin (Assay Media). For the mGlu3 TREx293 cells, this assay medium was also supplemented with 25 ng/mL tetracycline for 20 hours. Plated cells were incubated overnight at 37 °C in the presence of 5% CO<sub>2</sub>. The following day, plated cells had their medium exchanged to Assay Buffer (Hanks Balanced Salt Solution (Invitrogen) containing 20 mM HEPES and 2.5 mM probenacid, pH 7.3) using an ELX405 microplate washer (BioTek), leaving 20 μL/well, followed by addition of with 20 μL of 4.5 μM Fluo 4 AM (Invitrogen, Carlsbad, CA) prepared as a 2.3 mM stock in DMSO and mixed in a 1:1 ratio with 10 percent (w/v) pluronic acid F-127 and diluted in Assay Buffer for 45 min at 37 °C. The dye was then exchanged to Assay Buffer using an ELX405, leaving 20 μL/well and the plates were incubated at room temperature for 10 min prior to assay. For concentration-response curve experiments, compounds were serially diluted 1:3 into 10 point concentration response curves in DMSO, were transferred to daughter plates using an Echo acoustic plate reformatter (Labcyte, Sunnyvale, CA), and diluted into Assay Buffer to generate a 2× stock. Calcium flux was measured using the Functional Drug Screening System 6000 or 7000 (FDSS6000 or FDSS7000, Hamamatsu, Japan). Baseline readings were taken (10 images at 1 Hz, excitation, 470+/−20 nm, emission, 540+/−30 nm) and then 20 μL/well test compounds were added using the FDSS’s integrated pipettor. Approximately 2.5 minutes later an EC<sub>20</sub> concentration of glutamate (10 μL of a 5× final concentration) was added followed approximately 2.0 minutes later by an EC<sub>80</sub> concentration of glutamate (12 μL of a 5× final concentration). For fold shift experiments, compounds were added at 2X their final concentration and then increasing concentrations of glutamate were added in the presence of vehicle or the appropriate concentration of test compound. Curves were fitted using a four point logistical equation using Microsoft XLfit (IDBS, Bridgewater, NJ). Subsequent confirmations of concentration response parameters were performed using independent serial dilutions of source compounds and data from multiple days experiments were integrated and fit using a four point logistical equation in GraphPad Prism (GraphPad Software, Inc., La Jolla, CA).</p><p><b>Thallium flux assays.</b> Compound activity at the group II and group III mGlus was assessed using thallium flux through GIRK channels, a method that has been described in detail.<a class="bibr" href="#ml337.r1" rid="ml337.r1">1</a> Briefly, cells were plated into 384 well, black-walled, clear-bottom poly-D-lysine coated plates (Greiner) at a density of 15,000 cells/20 μL/well in DMEM containing 10% dialyzed FBS, 20 mM HEPES, and 100 units/ml penicillin/streptomycin (Assay Media). Plated cells were incubated overnight at 37 °C in the presence of 5% CO<sub>2</sub>. The following day, plated cells had their medium exchanged to Assay Buffer (Hanks Balanced Salt Solution (Invitrogen) containing 20 mM HEPES pH 7.3) using an ELX405 microplate washer (BioTek), leaving 20 μL/well, followed by addition of with 20 μL of 330 nM FluoZin-2 AM (Invitrogen, Carlsbad, CA) prepared as a 2.85 mM stock in DMSO and mixed in a 1:1 ratio with 10 percent (w/v) pluronic acid F-127 and diluted in Assay Buffer for 1 hour at room temperature. The dye was then exchanged to Assay Buffer using an ELX405, leaving 20 μL/well and the plates were incubated at room temperature for 10 min prior to assay. For concentration-response experiments, compounds were serially diluted 1:3 into 10 point concentration response curves in DMSO, were transferred to daughter plates using an Echo acoustic plate reformatter (Labcyte, Sunnyvale, CA), and diluted into Assay Buffer to generate a 2X stock. Agonists were diluted in Thallium Buffer (125 mM sodium bicarbonate (added fresh the morning of the experiment), 1 mM magnesium sulfate, 1.8 mM calcium sulfate, 5 mM glucose, 12 mM thallium sulfate, 10 mM HEPES, pH 7.3) at 5X the final concentration to be assayed. Thallium flux was measured using the Functional Drug Screening System 6000 or 7000 (FDSS6000 or FDSS7000, Hamamatsu, Japan). Baseline readings were taken (10 images at 1 Hz, excitation, 470+/−20 nm, emission, 540+/−30 nm) and then 20 μL/well test compounds were added using the FDSS’s integrated pipettor. Approximately 2.5 minutes later 10 μL of Thallium Buffer +/− agonist was added. After the addition of agonist, data were collected for an approximately 3 additional min. Data were analyzed as described (Niswender et al., 2008). For fold shift experiments, compounds were added at 2X their final concentration and then increasing concentrations of glutamate were added in the presence of vehicle or the appropriate concentration of test compound. For selectivity experiments, full concentration-response curves of glutamate or L-AP4 (for mGlu<sub>7</sub>) were performed in the presence of a 10 μM concentration of compound, and compounds that affected the concentration-response by less than 2 fold in terms of potency or efficacy were designated as inactive.</p><p><b>DMPK Methods.</b>
|
|
<u><i>In vitro</i>:</u> The metabolism of <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> was investigated in rat hepatic microsomes (BD Biosciences, Billerica, MA) using substrate depletion methodology (% test article remaining). A potassium phosphate-buffered reaction mixture (0.1 M, pH 7.4) of test article (1 μM) and microsomes (0.5 mg/mL) was pre-incubated (5 min) at 37°C prior to the addition of NADPH (1 mM). The incubations, performed in 96-well plates, were continued at 37 °C under ambient oxygenation and aliquots (80 μL) were removed at selected time intervals (0, 3, 7, 15, 25 and 45 min). Protein was precipitated by the addition of chilled acetonitrile (160 μL), containing glyburide as an internal standard (50 ng/mL), and centrifuged at 3000 rpm (4°C) for 10 min. Resulting supernatants were transferred to new 96-well plates in preparation for LC/MS/MS analysis. The <i>in vitro</i> half-life (<i>t</i><sub>1/2</sub>, min, <a href="#ml337.eq1">Eq. 1</a>), intrinsic clearance (CL<sub>int</sub>, mL/min/kg, <a href="#ml337.eq2">Eq. 2</a>) and subsequent predicted hepatic clearance (CL<sub>hep</sub>, mL/min/kg, <a href="#ml337.eq3">Eq. 3</a>) were determined employing the following equations:</p><div class="pmc_disp_formula whole_rhythm clearfix" id="ml337.eq1"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow eleven_col">
|
|
<i>t</i><sub>1/2</sub> = Ln(2) / <i>k</i> ; where <i>k</i> represents the slope from linear regression analysis (% test article remaining)</div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap">1</span></div></div></div><div class="pmc_disp_formula whole_rhythm clearfix" id="ml337.eq2"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow eleven_col">
|
|
CL<sub>int</sub> = (0.693 / <i>t</i><sub>1/2</sub>) (rxn volume / mg of microsomes) (45 mg microsomes / gram of liver) (20<sup><i>a</i></sup> gm of liver / kg body weight); <sup><i>a</i></sup>scale-up factors of 20 (human) and 45 (rat)</div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap">2</span></div></div></div><div class="pmc_disp_formula whole_rhythm clearfix" id="ml337.eq3"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow eleven_col">
|
|
|
|
<math id="ml337.eq4" display="block"><semantics><mrow><mi>C</mi><mi>L</mi><mi>h</mi><mi>e</mi><mi>p</mi><mo>=</mo><mfrac><mrow><mi>Q</mi><mo>·</mo><mi>C</mi><mi>L</mi><mi> </mi><mtext>int</mtext></mrow><mrow><mi>Q</mi><mo>+</mo><mi>C</mi><mi>L</mi><mi> </mi><mtext>int</mtext></mrow></mfrac></mrow></semantics></math></div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap">3</span></div></div></div><p><b>Plasma Protein Binding.</b> Protein binding of <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> was determined in rat plasma via equilibrium dialysis employing Single-Use RED Plates with inserts (ThermoFisher Scientific, Rochester, NY). Briefly plasma (220 μL) was added to the 96 well plate containing test article (5 μL) and mixed thoroughly. Subsequently, 200 μL of the plasma-test article mixture was transferred to the <i>cis</i> chamber (red) of the RED plate, with an accompanying 350 μL of phosphate buffer (25 mM, pH 7.4) in the <i>trans</i> chamber. The RED plate was sealed and incubated 4 h at 37 °C with shaking. At completion, 50 μL aliquots from each chamber were diluted 1:1 (50 μL) with either plasma (<i>cis</i>) or buffer (<i>trans</i>) and transferred to a new 96 well plate, at which time ice-cold acetonitrile (2 volumes) was added to extract the matrices. The plate was centrifuged (3000 rpm, 10 min) and supernatants transferred to a new 96 well plate. The sealed plate was stored at −20 °C until LC/MS/MS analysis.</p><p><b>Liquid Chromatography/Mass Spectrometry Analysis</b>. <i>In vitro</i> experiments. <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> was analyzed via electrospray ionization (ESI) on an AB Sciex API-4000 (Foster City, CA) triple-quadrupole instrument that was coupled with Shimadzu LC-10AD pumps (Columbia, MD) and a Leap Technologies CTC PAL auto-sampler (Carrboro, NC). Analytes were separated by gradient elution using a Fortis C18 2.1 × 50 mm, 3.5 μm column (Fortis Technologies Ltd, Cheshire, UK) thermostated at 40 °C. HPLC mobile phase A was 0.1% NH<sub>4</sub>OH (pH unadjusted), mobile phase B was acetonitrile. The gradient started at 30% B after a 0.2 min hold and was linearly increased to 90% B over 0.8 min; held at 90% B for 0.5 min and returned to 30% B in 0.1 min followed by a re-equilibration (0.9 min). The total run time was 2.5 min and the HPLC flow rate was 0.5 mL/min. The source temperature was set at 500°C and mass spectral analyses were performed using multiple reaction monitoring (MRM) utilizing a Turbo-Ionspray® source in positive ionization mode (5.0 kV spray voltage). LC/MS/MS analysis was performed employing a TSQ Quantum<sup>ULTRA</sup> that was coupled to a ThermoSurveyor LC system (Thermoelectron Corp., San Jose, CA) and a Leap Technologies CTC PAL auto-sampler (Carrboro, NC). Chromatographic separation of analytes was achieved with an Acquity BEH C18 2.1 × 50 mm, 1.7 μm column (Waters, Taunton, MA).</p><div id="ml337.s4"><h3>2.1. Assays</h3><ul><li class="half_rhythm"><div><a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/602451" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 602451</a> (mGluR3_NAM_Summary)</div></li><li class="half_rhythm"><div><a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651840" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651840</a> (Negative Allosteric Modulators mGlu3 Galpha15 Calcium Potency)</div></li><li class="half_rhythm"><div><a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/623888" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 623888</a> (mGlu3_GIRK_Schild)</div></li><li class="half_rhythm"><div><a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651839" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651839</a> (Negative Allosteric Modulators, mGlu3 GIRK Potency)</div></li><li class="half_rhythm"><div><a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/623929" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 623929</a> (mGluR2_NAM)</div></li><li class="half_rhythm"><div><a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/588715" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 588715</a> (mGlu5_PAM_Secondary)</div></li><li class="half_rhythm"><div><a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651830" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651830</a> (<a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> mGlu3 NAM Competition in Radioligand Binding assays (Eurofins PanLabs)</div></li></ul></div><div id="ml337.s5"><h3>2.2. Probe Chemical Characterization</h3><p>Probe compound <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> (CID 60204017, <a href="https://pubchem.ncbi.nlm.nih.gov/substance/144223348" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">SID 144223348</a>) was prepared according <a class="figpopup" href="/books/NBK148852/figure/ml337.f3/?report=objectonly" target="object" rid-figpopup="figml337f3" rid-ob="figobml337f3">Scheme 1</a> and had the following characterization. <b>(<i>R</i>)-(2-fluoro-(4-((4-methoxyphenyl) ethynyl)phenyl)(3-(hydroxypiperidin-1-yl)methanone.</b> [α]<sub>D</sub><sup>23</sup> = −27.6° (<i>c =</i> 1, MeOH). LC (254 nm) 0.704 min (>99%); MS (ESI) <i>m/z</i> = 354.1. HRMS (TOF, ES+) C<sub>21</sub>H<sub>20</sub>FNO<sub>3.</sub>[M+H]<sup>+</sup> calc. mass 354.1505, found 354.1507. <sup>1</sup>H NMR (400.1 MHz, <i>d</i>6-DMSO) δ (ppm) [* = Rotamers]: 7.51 (d, <i>J</i> = 8.4 Hz, 2H); 7.46 (d, <i>J</i> = 10.2 Hz, 1H); 7.39 (m, 2H); 6.99 (d, <i>J</i> = 8.9 Hz, 2H); 5.00 (dd, <i>J</i><sub><i>1</i></sub> = 76.0 Hz, <i>J</i><sub><i>2</i></sub> = 4.2 Hz, 1H); 4.17 (m, 1H*); 3.78 (s, 3H); 3.32 (d, <i>J</i> = 12.5 Hz, 1H*); 3.19 (m, 1H*); 2.99 (m, 1H*); 2.89 (m, 1H); 1.75 (m, 2H); 1.37 (m, 2H). <sup>13</sup>C NMR (100.6 MHz, <i>d</i>6-DMSO) δ (ppm): 164.03 (d, <i>J</i> = 19.4 Hz), 160.31, 158.91, 156.47, 133.60, 129.39, 128.15 (d, <i>J</i> =9.7 Hz), 125.79, 124.90*, 124.77*, 118.52 (d, <i>J</i> =22.6 Hz), 114.87, 113.84, 91.91*, 91.88*, 86.73, 65.48*,65.32*, 55.69, 53.76, 48.68*, 47.05*, 41.82, 33.05*, 32.69*, 23.52.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figml337f3" co-legend-rid="figlgndml337f3"><a href="/books/NBK148852/figure/ml337.f3/?report=objectonly" target="object" title="Scheme 1" class="img_link icnblk_img figpopup" rid-figpopup="figml337f3" rid-ob="figobml337f3"><img class="small-thumb" src="/books/NBK148852/bin/ml337f3.gif" src-large="/books/NBK148852/bin/ml337f3.jpg" alt="Scheme 1. Probe preparation of ML337." /></a><div class="icnblk_cntnt" id="figlgndml337f3"><h4 id="ml337.f3"><a href="/books/NBK148852/figure/ml337.f3/?report=objectonly" target="object" rid-ob="figobml337f3">Scheme 1</a></h4><p class="float-caption no_bottom_margin">Probe preparation of ML337. </p></div></div><p><b>Solubility.</b> Solubility for <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> in PBS was determined to be 7.8 μM (3.2 μg/mL), which is ~13-fold higher than the cellular IC<sub>50</sub> for mGlu<sub>3</sub> inhibition.</p><p><b>GSH Conjugates.</b> No glutathione conjugates detected.</p><p><b>Stability.</b> Stability was determined for <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> at 23 °C in PBS (no antioxidants or other protectorants and DMSO concentration below 0.1%). See <a class="figpopup" href="/books/NBK148852/table/ml337.t1/?report=objectonly" target="object" rid-figpopup="figml337t1" rid-ob="figobml337t1">Table 1</a>. After 48 hours, ~35% of the initial concentration of <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> remained in solution. The loss is most likely due to limited solubility in buffer. In plasma, <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> is very stable <i>in vitro</i> as well as <i>in vivo</i> (<i>vide infra</i>).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml337t1"><a href="/books/NBK148852/table/ml337.t1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figml337t1" rid-ob="figobml337t1"><img class="small-thumb" src="/books/NBK148852/table/ml337.t1/?report=thumb" src-large="/books/NBK148852/table/ml337.t1/?report=previmg" alt="Table 1. Stability of ML337." /></a><div class="icnblk_cntnt"><h4 id="ml337.t1"><a href="/books/NBK148852/table/ml337.t1/?report=objectonly" target="object" rid-ob="figobml337t1">Table 1</a></h4><p class="float-caption no_bottom_margin">Stability of ML337. </p></div></div><p>MLS004580699 (<a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a>, CID 60204017, 26.0 mg); MLS004580700 (CID 60204018, 5.7 mg); MLS004580701 (CID 60210783, 5.2 mg); MLS004580702 (CID 60210757, 5.0 mg); MLS004580703 (CID 60204019, 5.1 mg); MLS004580704 (CID 60210795; 4.8 mg)</p></div><div id="ml337.s6"><h3>2.3. Probe Preparation</h3><p>Probe compound <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> (CID 60204017, <a href="https://pubchem.ncbi.nlm.nih.gov/substance/144223348" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">SID 144223348</a>) was prepared according to <a class="figpopup" href="/books/NBK148852/figure/ml337.f4/?report=objectonly" target="object" rid-figpopup="figml337f4" rid-ob="figobml337f4">Scheme 2</a> and had the following characterization. <b>(<i>R</i>)-(2-fluoro-(4-((4-methoxyphenyl) ethynyl)phenyl)(3-(hydroxypiperidin-1-yl)methanone. 2-fluoro-4-((4-methoxyphenyl)ethynyl)benzoic acid, (6).</b> To a solution of 4-Iodo-2-fluorobenzoic acid (798 mg, 3 mmol) in N,N’-dimethyformamide (5 mL) was added CuI (23 mg, 0.12 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub> (70 mg, 0.06 mmol), Diethylamine (241 mg, 3.3 mmol), and 1-ethynyl-4-methoxybenzene (475 mg, 3.6 mmol) under argon in a sealed microwave vial. The mixture was allowed to stir and was placed in a microwave reactor and heated to 100 °C for 1 hour. The reaction was allowed to cool to room temperature and was diluted with EtOAc (10 mL), washed with water (10 mL), 5% LiCl (aqueous, 2 × 10 mL), and brine (10 mL). The organic layer was passed through a Celite pad, dried with MgSO4, filtered, and solvent was removed under vacuum. <b>6</b> (750 mg, 92.5%) was isolated following purification on HPLC. LC (254nm) 0.752min (>99%); MS (ESI) <i>m/z</i> = 271.1, C<sub>16</sub>H<sub>11</sub>FO<sub>3</sub></p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figml337f4" co-legend-rid="figlgndml337f4"><a href="/books/NBK148852/figure/ml337.f4/?report=objectonly" target="object" title="Scheme 2" class="img_link icnblk_img figpopup" rid-figpopup="figml337f4" rid-ob="figobml337f4"><img class="small-thumb" src="/books/NBK148852/bin/ml337f4.gif" src-large="/books/NBK148852/bin/ml337f4.jpg" alt="Scheme 2. Probe preparation of ML337." /></a><div class="icnblk_cntnt" id="figlgndml337f4"><h4 id="ml337.f4"><a href="/books/NBK148852/figure/ml337.f4/?report=objectonly" target="object" rid-ob="figobml337f4">Scheme 2</a></h4><p class="float-caption no_bottom_margin">Probe preparation of ML337. </p></div></div><p><b>(<i>R</i>)-(2-fluoro-4-((4-methoxyphenyl)ethynyl)phenyl)(3-hydroxypiperidin-1-yl)methanone, (7, <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a>).</b> To a solution of compound <b>2</b> (675 mg, 2.5 mmol) in 20 mL DMF, was added diisopropylethylamine (1.07 g, 8.25 mmol) while stirring. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (560 mg, 3 mmol), hydroxybenzotriazole (337 mg, 2.5 mmol), and (R)-3-hydroxypiperidine hydrochloride (342 mg, 2.5 mmol) were then added. The reaction was allowed to stir for 4 hours at room temperature, then quenched with a solution of saturated NaHCO<sub>3</sub> (20 mL), washed with 5% LiCl (aqueous, 2 × 20 mL), and brine (20 mL). The reaction was extracted into dichloromethane (50 mL), and solvent was removed under vacuum. The residue was purified using HPLC, and amine <b>3</b> was obtained as an ivory solid (420 mg, 47%). [α]<sub>D</sub><sup>23</sup> = −27.6° (<i>c =</i> 1, MeOH). LC (254 nm) 0.704 min (>99%); MS (ESI) <i>m/z</i> = 354.1. HRMS (TOF, ES+) C<sub>21</sub>H<sub>20</sub>FNO<sub>3.</sub>[M+H]<sup>+</sup> calc. mass 354.1505, found 354.1507. <sup>1</sup>H NMR (400.1 MHz, <i>d</i>6-DMSO) δ (ppm) [* = Rotamers]: 7.51 (d, <i>J</i> = 8.4 Hz, 2H); 7.46 (d, <i>J</i> = 10.2 Hz, 1H); 7.39 (m, 2H); 6.99 (d, <i>J</i> = 8.9 Hz, 2H); 5.00 (dd, <i>J</i><sub><i>1</i></sub> = 76.0 Hz, <i>J</i><sub><i>2</i></sub> = 4.2 Hz, 1H); 4.17 (m, 1H*); 3.78 (s, 3H); 3.32 (d, <i>J</i> = 12.5 Hz, 1H*); 3.19 (m, 1H*); 2.99 (m, 1H*); 2.89 (m, 1H); 1.75 (m, 2H); 1.37 (m, 2H). <sup>13</sup>C NMR (100.6 MHz, <i>d</i>6-DMSO) δ (ppm): 164.03 (d, <i>J</i> = 19.4 Hz), 160.31, 158.91, 156.47, 133.60, 129.39, 128.15 (d, <i>J</i> =9.7 Hz), 125.79, 124.90*, 124.77*, 118.52 (d, <i>J</i> =22.6 Hz), 114.87, 113.84, 91.91*, 91.88*, 86.73, 65.48*,65.32*, 55.69, 53.76, 48.68*, 47.05*, 41.82, 33.05*, 32.69*, 23.52.</p></div></div><div id="ml337.s7"><h2 id="_ml337_s7_">3. Results</h2><div id="ml337.s8"><h3>3.1. Dose Response Curves for Probe</h3><div id="ml337.f1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20In%20vitro%20molecular%20pharmacology%20characterization%20of%20ML337%20and%20three%20closely%20related%20mGlu3%20NAMs.&p=BOOKS&id=148852_ml337f1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK148852/bin/ml337f1.jpg" alt="Figure 1. In vitro molecular pharmacology characterization of ML337 and three closely related mGlu3 NAMs." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title"><i>In vitro</i> molecular pharmacology characterization of ML337 and three closely related mGlu<sub>3</sub> NAMs</span></h3><div class="caption"><p>Concentration-response curves of mGlu<sub>2</sub> and mGlu<sub>3</sub> calcium (antagonist mode) for the four lead mGlu<sub>3</sub> NAMs, including <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a>. All four provide complete inhibition of mGlu<sub>3</sub> and are devoid of activity at mGlu<sub>2</sub>. In addition, all four have no activity (PAM or NAM) at mGlu<sub>1,4,5,6,7,8</sub>.</p></div></div></div><div id="ml337.s9"><h3>3.2. Cellular Activity</h3><p>The primary screening assays (both GIRK and Calcium) are cell-based assays, indicating that <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> can gain access to its molecular target when applied to cells. The compound did not exhibit acute toxicity in cell based assays at concentrations up to 30 μM, and cytotoxicity assays aimed at this parameter indicated <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> had no cytotoxicity in non-transformed HEK293.</p></div><div id="ml337.s10"><h3>3.3. Profiling Assays</h3><p>To more fully characterize this potent, selective mGlu<sub>3</sub> NAM <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> was tested using Ricerca’s (formerly MDS Pharma’s) Lead Profiling Screen (binding assay panel of 68 GPCRs, ion channels and transporters screened at 10 μM).<a class="bibr" href="#ml337.r2" rid="ml337.r2">2</a> Included in the Ricerca screening panel are a number of ion channels (Calcium Channel, L-Type and N-Type; Potassium channel [K<sub>ATP</sub>]; Potassium channel [hERG]) and class A GPCRs (D<sub>1–5</sub>, H<sub>1–3</sub>, etc.). <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> was found to only inhibit two targets (DAT: 71%@10 μM and 5-HT<sub>2B</sub> 74%@10 μM) out of the 68 assays (<a class="figpopup" href="/books/NBK148852/table/ml337.t2/?report=objectonly" target="object" rid-figpopup="figml337t2" rid-ob="figobml337t2">Table 2</a>) conducted (inhibition of radio ligand binding > 50% at 10 μM).<a class="bibr" href="#ml337.r2" rid="ml337.r2">2</a>
|
|
<a href="/pcsubstance/?term=ML289[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML289</a> hit the same two targets, but at 88% and 77% inhibition@ 10 μM, respectively for DAT and 5-HT<sub>2B</sub>. <a class="figpopup" href="/books/NBK148852/table/ml337.t3/?report=objectonly" target="object" rid-figpopup="figml337t3" rid-ob="figobml337t3">Table 3</a> highlights calculated properties for <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a>, which compares favorably with the MDDR.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml337t2"><a href="/books/NBK148852/table/ml337.t2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img figpopup" rid-figpopup="figml337t2" rid-ob="figobml337t2"><img class="small-thumb" src="/books/NBK148852/table/ml337.t2/?report=thumb" src-large="/books/NBK148852/table/ml337.t2/?report=previmg" alt="Table 2. Ricerca Profiling of ML337." /></a><div class="icnblk_cntnt"><h4 id="ml337.t2"><a href="/books/NBK148852/table/ml337.t2/?report=objectonly" target="object" rid-ob="figobml337t2">Table 2</a></h4><p class="float-caption no_bottom_margin">Ricerca Profiling of ML337. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml337t3"><a href="/books/NBK148852/table/ml337.t3/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img figpopup" rid-figpopup="figml337t3" rid-ob="figobml337t3"><img class="small-thumb" src="/books/NBK148852/table/ml337.t3/?report=thumb" src-large="/books/NBK148852/table/ml337.t3/?report=previmg" alt="Table 3. Calculated Property Comparison with MDDR Compounds." /></a><div class="icnblk_cntnt"><h4 id="ml337.t3"><a href="/books/NBK148852/table/ml337.t3/?report=objectonly" target="object" rid-ob="figobml337t3">Table 3</a></h4><p class="float-caption no_bottom_margin">Calculated Property Comparison with MDDR Compounds. </p></div></div></div></div><div id="ml337.s11"><h2 id="_ml337_s11_">4. Discussion</h2><div id="ml337.s12"><h3>4.1. Comparison to Existing Art and How the New Probe is an Improvement</h3><p><a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> (CID 60204017) is the most potent (IC<sub>50</sub> = 592 nM, 0.3%) and selective mGlu<sub>3</sub> NAM reported to date with >50-fold selectivity vs. mGlu<sub>2</sub> and inactive on mGlu<sub>1,4,5,6,7,8</sub>. The existing art, represented by <b>1–3</b> (see <a class="figpopup" href="/books/NBK148852/figure/ml337.f2/?report=objectonly" target="object" rid-figpopup="figml337f2" rid-ob="figobml337f2">Figure 2</a>), are inferior to the probe <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> in terms of both potency and mGlu<sub>3</sub> selectivity. <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> can be used both <i>in vitro</i> and <i>in vivo</i> to study the role of selective inhibition of mGlu<sub>3</sub> in the CNS in a manner previously unavailable with the prior art compounds. Moreover, <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> possess an attractive <i>in vitro</i> and <i>in vivo</i> DMPK profile, ancillary pharmacology (only two activities at 10 μM in the Ricerca Panel) and affords excellent CNS exposure in both mouse (brain:plasma ratio of 0.92) and rat (brain:plasma ratio of 0.3). <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> can be used for basic biochemical and electrophysiological experiments as well as to help establish potential utility for mGlu<sub>3</sub> inhibition as a target for a wide variety of important CNS therapeutic indications. Finally, <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a> is free from IP constraints, which will allow the MLPCN to freely provide this probe to the biomedical research community.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figml337f2" co-legend-rid="figlgndml337f2"><a href="/books/NBK148852/figure/ml337.f2/?report=objectonly" target="object" title="Figure 2" class="img_link icnblk_img figpopup" rid-figpopup="figml337f2" rid-ob="figobml337f2"><img class="small-thumb" src="/books/NBK148852/bin/ml337f2.gif" src-large="/books/NBK148852/bin/ml337f2.jpg" alt="Figure 2. Structures of mGlu3 NAMs RO4491533 (1) and LY2399575 (2), both dual mGlu2/mGlu3 NAMs, and the first mGlu3 selective NAM, ML289, with ~15-fold selectivity versus mGlu2." /></a><div class="icnblk_cntnt" id="figlgndml337f2"><h4 id="ml337.f2"><a href="/books/NBK148852/figure/ml337.f2/?report=objectonly" target="object" rid-ob="figobml337f2">Figure 2</a></h4><p class="float-caption no_bottom_margin">Structures of mGlu<sub>3</sub> NAMs RO4491533 (1) and LY2399575 (2), both dual mGlu<sub>2</sub>/mGlu<sub>3</sub> NAMs, and the first mGlu<sub>3</sub> selective NAM, ML289, with ~15-fold selectivity versus mGlu<sub>2</sub>. </p></div></div></div></div><div id="ml337.s13"><h2 id="_ml337_s13_">5. References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="ml337.r1">Niswender CM, Johnson KA, Luo Q, Ayala JE, Kim C, Conn PJ, Weaver CD. <span><span class="ref-journal">Mol. Pharm. </span>2008;<span class="ref-vol">73</span>:1213–1224.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18171729" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18171729</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="ml337.r2">For full information on the targets in the Lead Profiling Screen at Ricerca, please see: <a href="http://www.ricerca.com" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">www<wbr style="display:inline-block"></wbr>​.ricerca.com</a></div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK148852_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Cody Wenthur</span>, <span itemprop="author">J. Scott Daniels</span>, <span itemprop="author">Ryan Morrison</span>, <span itemprop="author">Julie L. Engers</span>, <span itemprop="author">Colleen M. Niswender</span>, <span itemprop="author">P. Jeffrey Conn</span>, and <span itemprop="author">Craig W. Lindsley</span><sup>,*</sup>.</p><h4>Affiliations</h4><div class="affiliation"><sup>1</sup> Vanderbilt Specialized Chemistry Center, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center</div><div class="affiliation">
|
|
<sup>*</sup>
|
|
<span class="before-email-separator"></span><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.tlibrednav@yelsdnil.giarc" class="oemail">ude.tlibrednav@yelsdnil.giarc</a></div><h3>Publication History</h3><p class="small">Received: <span itemprop="datePublished">December 10, 2012</span>; Last Update: <span itemprop="dateModified">March 22, 2013</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p>National Center for Biotechnology Information (US), Bethesda (MD)</p><h3>NLM Citation</h3><p>Wenthur C, Daniels JS, Morrison R, et al. Development of a Second Generation mGlu3 NAM Probe. 2012 Dec 10 [Updated 2013 Mar 22]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/mlprobe/ml338/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/mlprobe/ml336/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="fig" id="figobml337fu1"><div id="ml337.fu1" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK148852/bin/ml337fu1.jpg" alt="ML337." /></div><h3><span class="title">ML337</span></h3></div></article><article data-type="table-wrap" id="figobml337tu1"><div id="ml337.tu1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK148852/table/ml337.tu1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml337.tu1_lrgtbl__"><table><thead><tr><th id="hd_h_ml337.tu1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CID/ML#</th><th id="hd_h_ml337.tu1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Target Name</th><th id="hd_h_ml337.tu1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IC<sub>50</sub>/ (nM) [SID, AID]</th><th id="hd_h_ml337.tu1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anti-target Name(s)</th><th id="hd_h_ml337.tu1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IC<sub>50</sub> (μM) [SID, AID]</th><th id="hd_h_ml337.tu1_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Fold Selective</th><th id="hd_h_ml337.tu1_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Secondary Assay(s) Name: IC<sub>50</sub>/EC<sub>50</sub> (nM) [SID, AID]</th></tr></thead><tbody><tr><td headers="hd_h_ml337.tu1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CID 60204017/<a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a></td><td headers="hd_h_ml337.tu1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">mGlu<sub>3</sub><br />(calcium)</td><td headers="hd_h_ml337.tu1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">592 nM, 0.3% [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/144223348" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">SID 144223348</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/602451" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 602451</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651840" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651840</a>]</td><td headers="hd_h_ml337.tu1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">mGlu<sub>2</sub><br /><br />mGlu<sub>1,4,5,6,7,8</sub></td><td headers="hd_h_ml337.tu1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>30 μM<br /><br />>30 μM<br /><br />[<a href="https://pubchem.ncbi.nlm.nih.gov/substance/144223348" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">SID 144223348</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/623929" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 623929</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/588715" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 588715</a>]</td><td headers="hd_h_ml337.tu1_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>50-fold<br />>50-fold</td><td headers="hd_h_ml337.tu1_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">mGlu<sub>3</sub> (GIRK)<br /><br />1.48 μM, −4.4%<br /><br />[<a href="https://pubchem.ncbi.nlm.nih.gov/substance/144223348" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">SID 144223348</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/651830" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 651830</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/623885" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 623885</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/588715" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">AID 588715</a>]</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobml337f3"><div id="ml337.f3" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK148852/bin/ml337f3.jpg" alt="Scheme 1. Probe preparation of ML337." /></div><h3><span class="label">Scheme 1</span><span class="title">Probe preparation of ML337</span></h3></div></article><article data-type="table-wrap" id="figobml337t1"><div id="ml337.t1" class="table"><h3><span class="label">Table 1</span><span class="title">Stability of ML337</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK148852/table/ml337.t1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml337.t1_lrgtbl__"><table class="no_top_margin"><thead><tr><th id="hd_h_ml337.t1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></th><th id="hd_h_ml337.t1_1_1_1_2" colspan="6" rowspan="1" style="text-align:center;vertical-align:top;">Percent Remaining (%)</th></tr><tr><th headers="hd_h_ml337.t1_1_1_1_1" id="hd_h_ml337.t1_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Compound</th><th headers="hd_h_ml337.t1_1_1_1_2" id="hd_h_ml337.t1_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0 Min</th><th headers="hd_h_ml337.t1_1_1_1_2" id="hd_h_ml337.t1_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">15 Min</th><th headers="hd_h_ml337.t1_1_1_1_2" id="hd_h_ml337.t1_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">30 Min</th><th headers="hd_h_ml337.t1_1_1_1_2" id="hd_h_ml337.t1_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">90 Min</th><th headers="hd_h_ml337.t1_1_1_1_2" id="hd_h_ml337.t1_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">24 Hour</th><th headers="hd_h_ml337.t1_1_1_1_2" id="hd_h_ml337.t1_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">48 Hour</th></tr></thead><tbody><tr><td headers="hd_h_ml337.t1_1_1_1_1 hd_h_ml337.t1_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;"><a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a>, CID 60204017</td><td headers="hd_h_ml337.t1_1_1_1_2 hd_h_ml337.t1_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">100</td><td headers="hd_h_ml337.t1_1_1_1_2 hd_h_ml337.t1_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">98</td><td headers="hd_h_ml337.t1_1_1_1_2 hd_h_ml337.t1_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">89</td><td headers="hd_h_ml337.t1_1_1_1_2 hd_h_ml337.t1_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">72</td><td headers="hd_h_ml337.t1_1_1_1_2 hd_h_ml337.t1_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">48</td><td headers="hd_h_ml337.t1_1_1_1_2 hd_h_ml337.t1_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">35</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobml337f4"><div id="ml337.f4" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Scheme%202.%20Probe%20preparation%20of%20ML337.&p=BOOKS&id=148852_ml337f4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK148852/bin/ml337f4.jpg" alt="Scheme 2. Probe preparation of ML337." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Scheme 2</span><span class="title">Probe preparation of ML337</span></h3></div></article><article data-type="fig" id="figobml337f1"><div id="ml337.f1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20In%20vitro%20molecular%20pharmacology%20characterization%20of%20ML337%20and%20three%20closely%20related%20mGlu3%20NAMs.&p=BOOKS&id=148852_ml337f1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK148852/bin/ml337f1.jpg" alt="Figure 1. In vitro molecular pharmacology characterization of ML337 and three closely related mGlu3 NAMs." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title"><i>In vitro</i> molecular pharmacology characterization of ML337 and three closely related mGlu<sub>3</sub> NAMs</span></h3><div class="caption"><p>Concentration-response curves of mGlu<sub>2</sub> and mGlu<sub>3</sub> calcium (antagonist mode) for the four lead mGlu<sub>3</sub> NAMs, including <a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a>. All four provide complete inhibition of mGlu<sub>3</sub> and are devoid of activity at mGlu<sub>2</sub>. In addition, all four have no activity (PAM or NAM) at mGlu<sub>1,4,5,6,7,8</sub>.</p></div></div></article><article data-type="table-wrap" id="figobml337t2"><div id="ml337.t2" class="table"><h3><span class="label">Table 2</span><span class="title">Ricerca Profiling of ML337</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK148852/table/ml337.t2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml337.t2_lrgtbl__"><table class="no_top_margin"><thead><tr><th id="hd_h_ml337.t2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CID/ML</th><th id="hd_h_ml337.t2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Structure</th><th id="hd_h_ml337.t2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Radioligand Binding Assay</th><th id="hd_h_ml337.t2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Species</th><th id="hd_h_ml337.t2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">% Inhibition (@ 10 μM)</th></tr></thead><tbody><tr><td headers="hd_h_ml337.t2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60204017/<a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a></td><td headers="hd_h_ml337.t2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<div class="graphic"><img src="/books/NBK148852/bin/ml337fu2.jpg" alt="Image ml337fu2.jpg" /></div></td><td headers="hd_h_ml337.t2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">DAT<br />5-HT<sub>2B</sub></td><td headers="hd_h_ml337.t2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">hum<br />hum</td><td headers="hd_h_ml337.t2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">71<br />74</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobml337t3"><div id="ml337.t3" class="table"><h3><span class="label">Table 3</span><span class="title">Calculated Property Comparison with MDDR Compounds</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK148852/table/ml337.t3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml337.t3_lrgtbl__"><table class="no_top_margin"><thead><tr><th id="hd_h_ml337.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Property</th><th id="hd_h_ml337.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;"><a href="/pcsubstance/?term=ML337[synonym]" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=pubchem">ML337</a></th><th id="hd_h_ml337.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">MDDR Phase I</th><th id="hd_h_ml337.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">MDDR Launched</th></tr></thead><tbody><tr><td headers="hd_h_ml337.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MW</td><td headers="hd_h_ml337.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">353.38</td><td headers="hd_h_ml337.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">438.98</td><td headers="hd_h_ml337.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">415.20</td></tr><tr><td headers="hd_h_ml337.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">cLogP</td><td headers="hd_h_ml337.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.51</td><td headers="hd_h_ml337.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.21</td><td headers="hd_h_ml337.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.21</td></tr><tr><td headers="hd_h_ml337.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">TPSA</td><td headers="hd_h_ml337.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">52.3</td><td headers="hd_h_ml337.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">97.06</td><td headers="hd_h_ml337.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">91.78</td></tr><tr><td headers="hd_h_ml337.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Hdon</td><td headers="hd_h_ml337.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.00</td><td headers="hd_h_ml337.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.12</td><td headers="hd_h_ml337.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.13</td></tr><tr><td headers="hd_h_ml337.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Hacc</td><td headers="hd_h_ml337.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.00</td><td headers="hd_h_ml337.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7.06</td><td headers="hd_h_ml337.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6.47</td></tr><tr><td headers="hd_h_ml337.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LogS</td><td headers="hd_h_ml337.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">−3.62</td><td headers="hd_h_ml337.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">−4.96</td><td headers="hd_h_ml337.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">−3.73</td></tr><tr><td headers="hd_h_ml337.t3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">NrotB</td><td headers="hd_h_ml337.t3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.87</td><td headers="hd_h_ml337.t3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7.08</td><td headers="hd_h_ml337.t3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5.71</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobml337f2"><div id="ml337.f2" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK148852/bin/ml337f2.jpg" alt="Figure 2. Structures of mGlu3 NAMs RO4491533 (1) and LY2399575 (2), both dual mGlu2/mGlu3 NAMs, and the first mGlu3 selective NAM, ML289, with ~15-fold selectivity versus mGlu2." /></div><h3><span class="label">Figure 2</span><span class="title">Structures of mGlu<sub>3</sub> NAMs RO4491533 (1) and LY2399575 (2), both dual mGlu<sub>2</sub>/mGlu<sub>3</sub> NAMs, and the first mGlu<sub>3</sub> selective NAM, ML289, with ~15-fold selectivity versus mGlu<sub>2</sub></span></h3></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script><script type="text/javascript" src="/core/mathjax/2.7.9/MathJax.js?config=TeX-AMS-MML_SVG"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|